admin
Good news, for about 90 days: U.S. Customs and Border Protection quietly pushed back a painful-sounding rule that would have made it much harder for Americans to get lower-cost prescriptions from abroad. The agency delayed the mandatory start of a new electronic filing process — Entry Type 13 in the Automated Commercial Environment — from October to January 20, 2027. That short reprieve matters to millions who rely on Canadian and other licensed foreign mail‑order pharmacies, but it does not fix the real problem. This is a pause, not a pardon.
What was delayed — and what wasn’t
Entry Type 13 is a new customs filing category that forces tighter data, bond and pre‑filing requirements on small international postal shipments that fall under a partner government agency like the FDA. In plain English: packages that previously cleared the mail with little fuss could be bumped into “formal entry” status, hit with fees, require bonds, be delayed, or even refused. CBP framed the change as a tool to stop illicit goods and fentanyl smuggling. That’s a worthy aim. But the mechanics of Entry Type 13 also sweep up ordinary, legal prescription shipments — and the 90‑day delay only postpones those headaches. The underlying de‑minimis exemption changes and new data rules remain in place.
Why this matters for patients and drug prices
About 2.3 million Americans are estimated to buy medicines from abroad to save money. For some seniors and chronically ill patients, that is not a luxury — it’s a lifeline. Tightening customs rules without a clear exemption for verified personal prescriptions threatens to raise out‑of‑pocket costs, force patients off medications, and push them into rationing. We’ve seen people stockpile meds ahead of the compliance date and members of Congress from both parties sounding alarms. A short delay helps, but it does nothing to stop drug manufacturers from cheering quietly in the background while patients watch their options shrink.
Where the politics get messy — and who should be accountable
President Donald Trump’s administration is right to take border threats seriously. Secretary of Homeland Security Markwayne Mullin and CBP Commissioner Rodney S. Scott have a job to secure the mail. But security and access are not mutually exclusive. Acting FDA Commissioner Kyle A. Diamantas and HHS Secretary Robert F. Kennedy Jr. also share responsibility to make sure public‑health rules don’t turn into a de facto protection racket for Big Pharma. If a rule designed to fight contraband instead denies Americans affordable medicine, the agencies need to say so and fix it. Otherwise we’re left with a bureaucratic victory lap and a political loss for patients.
Fixes to demand — and a clear call to action
Congress and the agencies should do three simple things before January: publish an explicit, verifiable exemption for legitimate personal‑use prescription shipments; coordinate the CBP Entry Type 13 process with FDA importation pathways so lawful imports aren’t choked by paperwork; and give states and patients real, practical options to access lower‑priced drugs from reputable foreign suppliers. Republicans who care about both law and liberty should not accept a rule that secures the border at the cost of raising drug prices. The 90‑day delay is a welcome breath, but not the outcome Americans deserve. Let’s use the time to fix the policy — not just rearrange the deck chairs on the high‑priced ship.
